Last reviewed · How we verify
NCT04584892: THIRd
Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities
trial testing Turoctocog alfa in Haemophilia A in 18 participants. Completed in 27 March 2023.
27 March 2023
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 18 |
| Start date | 12 April 2021 |
| Primary completion | 27 March 2023 |
| Estimated completion | 27 March 2023 |
| Sites | 10 locations across Italy |
Drugs / interventions tested
- Turoctocog alfa (TUROCTOCOG ALFA) — full drug profile →
Conditions studied
- Haemophilia A — all drugs for Haemophilia A →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
12 and older, any sex, with Haemophilia A. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study on Italian patients with haemophilia A in prophylaxis treatment with Turoctocog alfa under routine clinical conditions. The purpose of the study is to investigate the therapeutic scheme in a population of patients treated with Turoctocog alfa and to investigate the participation in recreational activities, the level of physical activity, and quality of life. Participants will get NovoEight® (Turoctocog alfa) as prescribed to them by the study doctor. The study will last for about 12 months. Participants will be requested to fill in the Questionnaires investigating the participation in recreational activities, the level of physical activity, and quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04584892
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Turoctocog alfa
Trials testing the same drug.
- NCT06574984 — Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients · recruiting
- NCT03588741 — Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A · Phase 3 · terminated
- NCT03196297 — A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia · Phase 2 · completed
Other recruiting trials for Haemophilia A
Currently open trials in the same condition.
- NCT07238816 — A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People · Phase 1 · recruiting
- NCT07220564 — A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A · Phase 1 · recruiting
- NCT06574984 — Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients · recruiting
- NCT07437404 — Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. · Phase 3 · recruiting
- NCT05685238 — A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4) · Phase 3 · active not recruiting
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04584892 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 28 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04584892.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing